ArticleNature communications2024
Phage Paride can kill dormant, antibiotic-tolerant cells of Pseudomonas aeruginosa by direct lytic replication.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 52 citations in OpenAlex.
- When phage restriction is not immunity: Immune gates, replication-niche barriers, and assay-limited phenotypes.Engineering microbiology · 2026Article
- Phage vB_KpnM_NB cocktail synergizing with amikacin in inhibiting persister cells ofApplied and environmental microbiology · 2026Article
- Phage therapy: from basic biology to clinical application.Nature reviews. Microbiology · 2026Review
- PMI TechNote: Bacteriophages-From the Petri Dish to Conquering the Nooks and Crannies of Difficult-to-Treat Infections.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Review
- Complete genome sequence ofMicrobiology resource announcements · 2026Article
- Isolation of a Novel Lytic Pseudomonas aeruginosa Phage Henu5 and Fitness Costs of Phage-Driven Resistance.Microbial biotechnology · 2026Article
- From hype to hope: reanimating phage therapy through evidence-based multidisciplinarity.Nature communications · 2026Review
- Engineered Bacteriophages: A Next-Generation Platform for Precision Antimicrobials and Therapeutics.Viruses · 2026Review
- Review
- Pseudolysogeny-mediated evolutionary trade-offs favor phage therapy by limiting antibiotic resistance and virulence in Cutibacterium acnes.Scientific reports · 2026Article
- Targeted elimination of Staphylococcus aureus mastitis infections with synthetic phage-based CRISPR-Cas delivery systems.NPJ biofilms and microbiomes · 2026Article
- Phage-Based Approaches to ChronicAntibiotics (Basel, Switzerland) · 2026Review
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases.Frontiers in cellular and infection microbiology · 2026Review
- The opposite effects of stringent response on phage infection ofmicroLife · 2026Article
- Article
- Antibiotic Persister Cells in Acinetobacter baumannii: Overview of Molecular Mechanisms and Removal Strategies.Environmental microbiology · 2025Review
- CRISPR-Cas9 enables efficient genome engineering of the strictly lytic, broad-host-range staphylococcal bacteriophage K.Applied and environmental microbiology · 2025Article
- Recent advances in the understanding, detection and therapeutic targeting of bacterial recalcitrance.BMC microbiology · 2025Review
- Phage-Antibiotic Combinations for Pseudomonas: Successes in the Clinic and In Vitro Tenuously Connected.Microbial biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Bacteriophages are ubiquitous viral predators that have primarily been studied using fast-growing laboratory cultures of their bacterial hosts. However, microbial life in nature is mostly in a slow- or non-growing, dormant state. Here, we show that diverse phages can infect deep-dormant bacteria and suspend their replication until the host resuscitates ("hibernation"). However, a newly isolated Pseudomonas aeruginosa phage, named Paride, can directly replicate and induce the lysis of deep-dormant hosts. While non-growing bacteria are notoriously tolerant to antibiotic drugs, the combination with Paride enables the carbapenem meropenem to eradicate deep-dormant cultures in vitro and to reduce a resilient bacterial infection of a tissue cage implant in mice. Our work might inspire new treatments for persistent bacterial infections and, more broadly, highlights two viral strategies to infect dormant bacteria (hibernation and direct replication) that will guide future studies on phage-host interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.